103686-16-4

Basic information

• Product Name: 3-(4-Bromo-2-thienyl)acrylic acid
• Synonyms: trans-3-(4-Bromothiophen-2-yl)acrylic acid
• CAS NO: 103686-16-4
• Molecular Formula: C₇H₅BrO₂S
• Molecular Weight: 233.08
• Product Categories: Building Blocks;C7 to C9;Chemical Synthesis;Halogenated Heterocycles;Heterocyclic Building Blocks;Thiophenes
• Mol File: 103686-16-4.mol

Chemical Properties

• Melting Point: 168-173℃
• Appearance: /
• CAS DataBase Reference: 3-(4-Bromo-2-thienyl)acrylic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 3-(4-Bromo-2-thienyl)acrylic acid(103686-16-4)
• EPA Substance Registry System: 3-(4-Bromo-2-thienyl)acrylic acid(103686-16-4)

Safety Data

• Hazard Codes: Xi
• Statements: 36/37/38
• Safety Statements: 26-36/37
• WGK Germany: 3
• Hazardous Substances Data: 103686-16-4(Hazardous Substances Data)

Usage

General Description

3-(4-Bromo-2-thienyl)acrylic acid is a chemical compound with the molecular formula C7H5BrO2S. It is a derivative of acrylic acid, with a 3-(4-Bromo-2-thienyl) group attached to the carbon-carbon double bond. 3-(4-Bromo-2-thienyl)acrylic acid is commonly used in the synthesis of pharmaceuticals and agrochemicals, as well as in the production of specialty polymers and materials. It has also been studied for its potential use in organic light-emitting diodes (OLEDs) and other electronic applications. 3-(4-Bromo-2-thienyl)acrylic acid is considered to be a valuable building block in organic synthesis, with a range of potential applications in various industries.

Upstream product

• 18791-75-8 4-Bromothiophen-2-aldehyde 
• 141-82-2 malonic acid 
• 98-03-3 thiophene-2-carbaldehyde 
• 110-89-4 piperidine 

Downstream Products

• 91150-58-2 3-(4'-bromo-2'-thiophenyl)-(E)-propenoic acid methyl ester 
• 799293-83-7 3-bromothieno[3,2-c]pyridin-4(5H)-one 
• 799293-85-9 3-bromo-4-amino-[3,2-c]-thienopyridine 
• 799293-91-7 3-bromo-7-iodothieno[3,2-c]pyridin-4-amine 
• 799293-86-0 4-amino-3-(3-chloro-4-fluoro-phenyl)-thieno[3,2-c]pyridine 
• 799293-87-1 4-amino-7-bromo-3-(3-chloro-4-fluorophenyl)-thieno[3,2-c]pyridine 
• 799293-92-8 4-amino-3-bromo-7-(3,4,5-trimethoxyphenyl)thieno[3,2-c]pyridine 
• 29064-82-2 3-bromo-4-chloro-[3,2-c]-thienopyridine 

Relevant articles and documents

Discovery of thienopyridines as Src-family selective Lck inhibitors

We describe the identification, SAR, and in vivo pharmacology of a new series of Src-family selective Lck inhibitors. These thienopyridines were designed based on a desire to access the unique residues in the extended hinge region of Lck.

Synthesis of Enantiomerically Pure Ring-Substituted l -Pyridylalanines by Biocatalytic Hydroamination

Current routes to nitrogen-containing heteroarylalanines involve complex multistep synthesis and are often reliant on protection/deprotection steps and wasteful chromatographic purifications. In order to complement existing methodologies, a convenient telescopic strategy was developed for the synthesis of l-pyridylalanine analogues (12 examples) and other l-heteroarylalanines (5 examples) starting from the corresponding aldehydes. A phenylalanine ammonia lyase (PAL) from Anabaena variabilis was used as the biocatalyst to give conversions ranging between 88 and 95%, isolated yields of 32-60%, and perfect enantiopurity (>99% ee) by employing an additional deracemization cascade where necessary.

NOVEL INHIBITOR COMPOUNDS OF PHOSPHODIESTERASE TYPE 10A

The present invention relates to novel compounds of the formula I which are inhibitors of phosphodiesterase type 10A and to their use for the manufacture of a medicament and which thus are suitable for treating or controlling of medical disorders selected from neurological disorders and psychiatric disorders, for ameliorating the symptoms associated with such disorders and for reducing the risk of such disorders

Structure-activity relationships of trans-substituted-propenoic acid derivatives on the nicotinic acid receptor HCA2 (GPR109A)

Nicotinic acid (niacin) has been used for decades as an antidyslipidemic drug in man. Its main target is the hydroxy-carboxylic acid receptor HCA2 (GPR109A), a G protein-coupled receptor. Other acids and esters such as methyl fumarate also interact with the receptor, which constituted the basis for the current study. We synthesized a novel series of substituted propenoic acids, such as fumaric acid esters, fumaric acid amides and cinnamic acid derivatives, and determined their affinities for the HCA2 receptor. We observed a rather restricted binding pocket on the receptor with trans-cinnamic acid being the largest planar ligand in our series with appreciable affinity for the receptor. Molecular modeling and analysis of the structure-activity relationships in the series suggest a planar trans-propenoic acid pharmacophore with a maximum length of 8 ? and out-of-plane orientation of the larger substituents.

Improved synthesis of 3-substituted-4-amino-[3,2-c]-thienopyridines

(Chemical Equation Presented) Two syntheses of 3-substituted-4-amino-[3,2- c]thienopyridines have been developed to replace the standard literature route to these compounds, which uses unattractive conditions involving azide and high temperatures. The fir

Heteroarylacrylamides and their use as pharmaceuticals for the stimulation of the expression of endothelial NO synthase

The present invention relates to heteroarylacrylamides of the formula I, in which Het, X, Ra, Rb, R1, R2 and R3 have the meanings indicated in the claims, which modulate the transcription of endotheli

Design and effective synthesis of novel templates, 3,7-diphenyl-4-amino-thieno and furo-[3,2-c]pyridines as protein kinase inhibitors and in vitro evaluation targeting angiogenetic kinases

A novel class of 3,7-diphenyl-4-amino-thieno and furo[3,2-c]pyridine has been designed based on pharmacophore models of ATP competitive kinase inhibitors. Versatile synthetic methods via double Suzuki coupling to explore SAR have been established and potent inhibitors against angiogenetic targets, VEGFR2, Tie-2, and EphB4, have been successfully discovered.

NOVEL CHEMICAL COMPOUNDS

This invention relates to newly identified compounds for treating and preventing tumors ans cancers, and methods for treating proliferative diseases associated with the imbalance or inappropriate activity of tyrosine kinases implicated in proliferative diseases.

Nitrogen containing heterocyclic compounds

Compounds of the formula (III): STR1 or salts or acyl derivatives thereof, for use as antifungal and antiprotozoal agents are disclosed. Compositions containing the compounds are also disclosed as are method for the preparation of the compounds and interm